Jacob Bell

Frederick, Washington, D.C.

Dad says I'm not an effective communicator. Senior Reporter @biopharmadive. Formerly @TheStreet, @educationweek, @mcclatchydc.

Articles

GSK targets neurodegenerative diseases with latest licensing deal

2 weeks ago | biopharmadive.com | Jacob Bell

GSK is betting potentially billions of dollars that a smaller drug company’s technology can help create new treatments for brain-corroding diseases. Through a licensing deal announced Sunday, GSK has gained access to drug delivery technology from South Korea’s ABL Bio.
M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals

2 weeks ago | biopharmadive.com | Jacob Bell

The world’s largest pharmaceutical companies mostly steered clear of billion-dollar acquisitions in the early months of this year, perhaps indicating how a tumultuous U.S. political environment has led would-be buyers to view bigger deals as too risky for the time being.
FDA approves first-of-its-kind RNA drug for hemophilia

3 weeks ago | biopharmadive.com | Jacob Bell

The Food and Drug Administration approved on Friday a new type of medicine for people with the rare bleeding disorder hemophilia. Current hemophilia treatments generally try to replace or spur the production of key blood-clotting proteins that are missing because of genetic mutations. But this newly approved medicine works differently. A snippet of genetic code, it gums up production of that keeps blood cells from sticking together.
FDA approves first-of-its-kind RNA drug for hemophilia

3 weeks ago | yahoo.com | Jacob Bell

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration approved on Friday a new type of medicine for people with the rare bleeding disorder hemophilia. Current hemophilia treatments generally try to replace or spur the production of key blood-clotting proteins that are missing because of genetic mutations. But this newly approved medicine works differently.
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen

3 weeks ago | biopharmadive.com | Jacob Bell

Eli Lilly plans to appeal a verdict from key drug regulators who say the company’s new treatment for Alzheimer’s disease should not be cleared for the European market. On Friday, the European Medicines Agency recommended that Lilly’s Kisunla not receive marketing authorization because its benefits don’t outweigh its potential risks.
Biogen plots new global headquarters in Kendall Square

1 month ago | biopharmadive.com | Jacob Bell

Biogen on Monday announced plans for a new global headquarters just steps away from its current one. The big biotechnology firm has signed a 15-year lease for approximately 580,000 square-feet of space at 55 Broadway in Cambridge, Massachusetts, which is part of a development project led by the Massachusetts Institute of Technology.
Novartis builds case for new SMA gene therapy

1 month ago | biopharmadive.com | Jacob Bell

On Wednesday, Novartis gave a more detailed look at long-awaited clinical data that the company believes will help secure a broad approval for a successor drug to its blockbuster gene therapy Zolgensma. The drug, code-named OAV101IT, shares the same active ingredient as Zolgensma, which in 2019 gained U.S. approval for the treatment of a rare, muscle-wasting illness known as spinal muscular atrophy.
Latigo raises $150M to get non-opioid pain drugs through key tests

1 month ago | biopharmadive.com | Jacob Bell

Latigo Biotherapeutics, a private drug company developing experimental pain medicines, has closed another nine-figure fundraising round. Asset manager Blue Owl Capital led the $150 million Series B round. As part of the raise, Kevin Raidy, a senior managing director at Blue Owl, has joined Latigo’s board of directors.
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

1 month ago | biopharmadive.com | Jacob Bell

Gene therapy specialist MeiraGTx is spinning some of its experimental medicines for the central nervous system into a startup that hopes to develop them further using artificial intelligence. Aptly named Hologen Neuro AI, the startup is a joint venture between MeiraGTx and Hologen, a healthcare-focused, generative AI firm that taps what’s known as real-world data to better understand the biology of diseases and how to treat them.
J&J scraps depression testing for potential blockbuster drug

1 month ago | biopharmadive.com | Jacob Bell

Johnson & Johnson is terminating some research for an experimental drug that the company previously predicted could be a multibillion-dollar product. In a statement released Thursday afternoon, J&J said it will stop developing the drug, called aticaprant, as an add-on therapy for patients with major depressive disorder.